Medicus Pharma Receives Positive FDA Feedback For Optimized Phase 2 Study Of Teverelix In AUR

Medicus Pharma said it received written FDA feedback and obtained central Institutional Review Board approval for a redesigned Phase 2 study of Teverelix in men after a first episode of acute urinary retention. This is a constructive regulatory milestone that supports continuation of the study design process, with likely modest positive read-through for the program.

Analysis

Medicus Pharma said it received written FDA feedback and obtained central Institutional Review Board approval for a redesigned Phase 2 study of Teverelix in men after a first episode of acute urinary retention. This is a constructive regulatory milestone that supports continuation of the study design process, with likely modest positive read-through for the program.